Our Research program spans the prostate cancer challenge from screening to the treatment of advanced disease.  We are exploring the latest methodologies for determining the aggressiveness of the cancers that go beyond the usual Gleason scoring system. These include biomarkers, Prostat Px Analysis, PC3 expression, and the use of sophisticated mapping and imaging technologies. We are also evaluating changes in diet and lifestyle that may delay or prevent the development of cancer in the normal prostate left after focal therapy is completed.

We are interested in the biology of prostate cancer and have participated in numerous research activities that relate to the 3D program. Drs. Thomas Flaig and Mike Glodé, working with Dr. Agarwal in the School of Pharmacy, headed the first trials designed to see whether extracts of Milk Thistle could be used to treat or prevent prostate cancer. If all known cancer is removed/destroyed by our 3D technology, we will continue to develop and do research on ways that could prevent new cancers from arising in the prostatic tissue that is still present. These might include studies of other natural products such as grape seed extract or legumes. We are also leaders in developing vaccines against prostate cancer that could be beneficial in stopping the disease before it develops.